TG Therapeutics, Inc. (TGTX)
TG Therapeutics develops and sells BRIUMVI, a treatment for multiple sclerosis, to physicians and patients. It last closed at $62.71 on Nov 17, down 0.08% on the day. The average 12-month price target from 2 analysts is $74.50 (+18.8% from the last close), with a high of $78.00 and a low of $71.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in TGTX, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $1.5M, the largest $941K.
Key Stats
Last 12 monthsNot reported for this period.
From TGTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on TGTX in the past 90 days. The average target is $74.50, with a high of $78.00 and a low of $71.00, compared with the last close of $62.71.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Evercore ISI Group | Maintained | Buy | $71 |
| Sep 1 | HC Wainwright & Co. | Target raised | Buy | $77 → $78 |
| Aug 7 | JP Morgan | Maintained | Buy | $72 |
| Jul 27 | B. Riley Securities | Maintained | Buy | $86 |
| Jul 13 | HC Wainwright & Co. | Target raised | Buy | $70 → $77 |
Technical Analysis
The stock is 5% above its 20 day and 9% above its 50 day average. It is 27% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 59). The nearest support is the Pivot at $62.59, and the nearest resistance the swing high (Nov 2) at $63.58.
| RSI (14) | 59.20 | Middle of its range | Neutral |
| MACD | 2.29 | Above its signal line | Bullish |
| Stochastic | 65.4 | Middle of its range | Neutral |
| ADX (14) | 22.4 | Weak trend | |
| Williams %R | -39.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 59.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.2% | Change over 10 sessions | Bullish |
| ATR (14) | $3.02 | Typical daily range, 4.8% of price |
| RSI (14) | 65.09 | Strong, overbought above 70 | Neutral |
| MACD | 4.71 | Above its signal line | Bullish |
| Stochastic | 78.4 | Middle of its range | Neutral |
| ADX (14) | 35.8 | Trending up | |
| Williams %R | -27.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 202.5 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +16.4% | Change over 10 sessions | Bullish |
| ATR (14) | $5.50 | Typical daily range, 8.8% of price |
What happened before
See how TGTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TGTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.
Whale Options Flow
90DNo whale options trades in TGTX in the last 90 days.
Dark Pool
30DTGTX Institutional Ownership
Full report →- ▲243 buying vs 183 selling
- ▲Held by funds +3.5 pts
- ▲Funds holding +24
- ▼Superinvestors: 2 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 455 | 431 | +5.6% |
| In funds' top 10 | 9 | 7 | +28.6% |
| Held by funds | 77.1% | 73.6% | +3.5 pts |
| New / increased | 76 / 167 | 101 / 149 | −2.8% |
| Reduced / sold out | 136 / 47 | 122 / 36 | +15.8% |
| Put/call ratio | 0.26 | 0.61 | −57.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TGTX is in one of them and how their past TGTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TGTX in an article yet. Here's the latest on the wider market.
TGTX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Donald J TrumpExecutive branch | Sell | $15K – $50K | Jan 26, 2026 | May 14, 2026 | 108 d |
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Mar 4, 2025 | May 14, 2026 | 436 d |
| Donald J TrumpExecutive branch | Buy | $50K – $100K | Feb 26, 2025 | May 14, 2026 | 442 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About TG Therapeutics
TG Therapeutics is a biotechnology company that develops and sells treatments for diseases driven by B cells, with its main focus on multiple sclerosis. Its approved product, BRIUMVI, is a monoclonal antibody given as an infusion lasting about an hour every 24 weeks to adults with relapsing forms of multiple sclerosis. Its customers include physicians and patients in the United States, and a commercial partner sells the treatment in several other countries. The company is based in Morrisville, North Carolina.
- Headquarters
- New York, NY
- Website
- tgtherapeutics.com ↗






